Fasted serum FGF-19 levels are reduced in individuals with overweight, obesity, and NAFLD and it has even been suggested as a diagnostic biomarker for NASH [17]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.